NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Compugen Ltd. CGEN
17 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in COMPUGEN LTD's annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.
Growth
USD 72.8M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 72.8 · Net income 35.3
Compound annual growth
Revenue compounded at +105.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
49 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 43.1% · Net 48.6%
ROE
FY2025 · ROE 44.8%
Each USD of equity produced 45 cents of profit this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 |
| Operating income $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Net income $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 0.38 | −0.16 | −0.21 | −0.39 | −0.41 | −0.37 | −0.43 | −0.41 | −0.72 | −0.62 | −0.40 | −0.26 | −0.36 | −0.38 | −0.35 | −0.22 | −0.13 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 44.8 | −23.6 | −26.2 | −36.5 | −30.2 | −37.6 | −72.4 | −67.9 | −79.9 | −41.1 | −20.6 | −16.1 | −56.8 | −73.2 | −50.2 | −25.9 | −14.0 |
| Shares out B | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 78 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 17 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2009